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 2 
Abstract 27 
Background: Given the potentially causal association of female genital schistosomiasis (FGS) 28 
with HIV-1 infection, improved diagnostics are urgently needed to scale-up FGS surveillance. The 29 
BILHIV (bilharzia and HIV) study assessed the performance of home-based self-collection 30 
methods (cervical and vaginal swabs) compared to cervicovaginal lavage (CVL) for the detection 31 
of Schistosoma DNA by real-time polymerase chain reaction (PCR).   32 
 33 
Methods: Between January and August 2018, a consecutive series of female participants from the 34 
Population-Cohort of the previous HIV prevention trial HPTN 071 (PopART), resident in 35 
Livingstone, Zambia were invited to take part in BILHIV if they were 18-31 years old, non-36 
pregnant and sexually active. Genital self-collected swabs and a urine specimen were obtained and 37 
a questionnaire completed at home visits. CVL was obtained at clinic follow-up.  38 
 39 
Results: 603 women self-collected genital swabs. Of these, 527 women had CVL performed by a 40 
mid-wife during clinic follow-up. Schistosoma DNA was more frequently detected in genital self-41 
collected specimens (24/603, 4.0%) compared to CVL (14/527, 2.7%). Overall, 5.0% (30/603) 42 
women had female genital schistosomiasis, defined as a positive PCR by any genital sampling 43 
method (cervical swab PCR, vaginal swab PCR, or CVL PCR) and 95% (573/603) did not have a 44 
positive genital PCR. The sensitivity of any positive genital self-collected swab against CVL was 45 
57.1% (95% CI 28.9 – 82.3%), specificity 97.3% (95.5 – 98.5%). In a subset of participants with 46 
active schistosome infection, determined by detectable urine Circulating Anodic Antigen (CAA) 47 
(15.1%, 91/601), positive PCR (4.3%, 26/601), or positive microscopy (5.5%, 33/603), the 48 
sensitivity of any positive self-collected specimen against CVL was 88.9% (51.8 – 99.7%).  49 
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 50 
Conclusions: Genital self-sampling increased the overall number of PCR-based FGS diagnoses in 51 
a field setting, compared with CVL. Home-based sampling may represent a scalable alternative 52 
method for FGS community-based diagnosis in endemic resource limited settings. 53 
 54 
Keywords: Female Genital Schistosomiasis, Genital self-sampling, Sensitivity, real-time PCR, 55 
Circulating Anodic Antigen (CAA) 56 
 57 
Author summary:  58 
Female Genital schistosomiasis (FGS) is a neglected and disabling disease that results when eggs 59 
from the waterborne parasite Schistosoma haematobium are trapped in the human reproductive 60 
tract. Current female genital schistosomiasis (FGS) diagnostic strategies are limited because they 61 
require expertise and equipment that may not be readily available in low income settings. Improved 62 
and accessible diagnostics are urgently needed to scale-up FGS surveillance. This is especially 63 
important as FGS has been associated with HIV-1 infection. The BILHIV (bilharzia and HIV) 64 
study assessed the performance of home-based self-collection methods (cervical and vaginal 65 
swabs) compared with a clinic-based cervicovaginal lavage (CVL) performed by a medical 66 
professional. Both methods used real-time polymerase chain reaction (PCR) to detect Schistosoma 67 
DNA. We found that, in a field setting, self-collected genital and cervical swabs increased the 68 
overall number of PCR-based FGS diagnoses, compared with clinically collected CVL. We report 69 
the sensitivity of self-collected swabs for the diagnosis of FGS, compared with CVL. We found 70 
that the sensitivity of self-collected genital swabs was higher in a subset of women with active 71 
schistosome infection. We suggest that home-based self-sampling may represent a scalable 72 
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community-based sampling platform for FGS community-based diagnosis in endemic resource 73 
limited settings. 74 
 75 
  76 
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Introduction: 77 
An estimated 82 million women in sub-Saharan Africa live with Schistosoma (S.) haematobium 78 
or S. mansoni infections (1) that follow fresh water contact. In Zambia alone, it is estimated that 79 
3.8 million people (approximately 22% of the population) are infected with Schistosoma species 80 
(2). After maturation, these trematode parasites commence egg-laying in the host’s venous system 81 
and disease occurs when tissue-entrapped eggs cause both local and systemic pathology (3). 82 
Female genital schistosomiasis (FGS), defined as the detection of eggs or Schistosoma spp. DNA 83 
in genital tissue or fluids (4), affects an estimated 20 - 56 million women worldwide (5), mostly in 84 
sub-Saharan Africa, including Zambia (6). The presence of eggs or Schistosoma spp. DNA in urine 85 
and stool does not confirm concurrent genital involvement (7, 8).  86 
 87 
Egg deposition in FGS occurs in clusters (9), often at the squamocolumnar junction in the 88 
subepithelial connective tissue (9) and is therefore frequently missed on superficial Papanicolaou-89 
smear based sampling (8-10). Often tissue-lodged eggs are accompanied by characteristic sandy 90 
patches (both grainy and homogenous) (11) and rubbery papules (12). However, in up to one-91 
quarter of cases, FGS occurs in macroscopically normal appearing cervical tissue (9, 13). 92 
Classically, FGS lesions are visualized colposcopically (8, 12), requiring equipment and trained 93 
clinical expertise that may not be available in low income settings (4). Also, concern that tissue 94 
biopsy, the proposed reference standard, may provide a means of entry for HIV-1 infection (4) has 95 
limited its use in FGS research. Given this theoretical risk, the use of polymerase chain reaction 96 
(PCR) on cervicovaginal lavage (CVL) has been advocated as an acceptable and less-invasive 97 
method of FGS diagnosis in research settings (8, 12, 14, 15). However, because CVL sampling 98 
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requires a trained health professional, vaginal speculum insertion, and an intact cold chain, it is 99 
not likely scalable for population – based FGS surveillance.  100 
 101 
FGS has been associated with adverse reproductive health outcomes, such as infertility (16), 102 
ectopic pregnancy (17, 18), and abortion (17). Eggs deposited in reproductive tissues release 103 
immunogenic antigens (19), resulting in granulomatous reaction and fibrosis (18). There is also 104 
increasing evidence on the association of FGS with prevalent HIV-1 infection (10, 20), a 105 
relationship that may be causal. Accurate, accessible, and affordable diagnostics are urgently 106 
needed to scale-up FGS surveillance and treatment. Schistosome infection is associated with a 107 
continuum of disease co-morbidities and post-infection complications (21). FGS can occur along 108 
this continuum and there is currently not a diagnostic test that captures the entire range of FGS 109 
clinical presentations (21).  110 
 111 
Self-sampling has been used for diagnosis of reproductive tract infections, including human 112 
papillomavirus (HPV) (22). Compared with clinician collected specimens, self-collected PCR-113 
based HPV testing is acceptable to participants (23), increases screening coverage (22, 24), and is 114 
as sensitive as clinician collected samples (25). A home-based diagnostic option for FGS with 115 
decreased reliance on medical professionals would have high field applicability. This study was 116 
designed to compare the performance of two home-based self-collection methods (cervical and 117 
vaginal swabs), to clinic-based, midwife-collected CVL for the detection of Schistosoma DNA by 118 
Nucleic Acid Amplification Tests (NAATs). 119 
 120 
Methods 121 
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Study Site and Subjects 122 
Between January and August 2018, participants from the Population Cohort (PC) of HPTN 071 123 
(PopART), a trial to measure the impact of an HIV combination prevention package, including 124 
universal HIV test and treat (26), were recruited to participate in the cross-sectional bilharzia and 125 
HIV (BILHIV) study. Women were eligible to participate if they were 18-31 years old, non-126 
pregnant, sexually active, and resident in one of the two communities (designated Community-A 127 
and Community-B) that participated in HPTN 071 (PopART) in Livingstone, Zambia. Central 128 
Livingstone is located within 5-10 kilometres of the Zambezi River, with a tributary flowing in 129 
close proximity to Community A. HPTN 071 (PopART) is a cluster randomized trial including 21 130 
participating communities. At the community level, the Population Cohort included one randomly 131 
selected adult 18 to 44 years of age from a random sample of households in each community (26). 132 
BILHIV study participants were then selected as a consecutive sample from the HPTN 071 133 
(PopART) Population Cohort. A 2013 survey of school aged children in Livingstone reported 134 
prevalence ranges for urinary S. haematobium infection between 3.3% and 73.3% (median 15.0%, 135 
mean 23.3%) (27).  136 
 137 
Home-Based Sample Collection and Questionnaire 138 
Trained community workers provided home visits to women who gave an “expression of interest” 139 
in the BILHIV study at the HPTN 071 (PopART) PC 36-month visit. The home visit included 140 
assessment of eligibility, a questionnaire, genital self-sampling (cervical and vaginal), and a single 141 
urine specimen. Trained field workers provided study information in the participant’s preferred 142 
language. Following written informed consent, a questionnaire containing questions regarding 143 
demographics, water contact, sexual behaviour, and genital symptoms, was administered. There 144 
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were no restrictions on the timing of urine sample self-collection, and 69.5% (419/603) were 145 
performed between 9:00 and 14:00. The community worker provided participating women with 146 
instructions for urine collection and cervical and vaginal self-sampling. Participants were 147 
instructed to hold a 6-inch PrimeSwab (Longhorn Diagnostics, Texas, USA) at the 2 3/8-inch score 148 
mark, insert the swab vaginally until their fingers touched the labia minora, and rotate the swab 149 
against the vaginal walls (minimum 15 repetitions) (Figure 1). Similarly, for the cervical swab, 150 
participants were instructed to hold a 6 3/4-inch flocked swab (Miraclean, Shenzen, China) with a 151 
quadrilateral kite-shaped tip at the non-flocked end, insert the swab until their fingers touched the 152 
labia minora and/or encountered resistance, and rotate the swab against the place of resistance 153 
(minimum 15 repetitions). Each flocked swab head was placed in individual screw cap microtubes 154 
(STARLAB, Hamburg, Germany) by the participant after the swab shaft was broken. Both swab 155 
specimens and urine were placed in cool boxes for transportation to the laboratory for further 156 
processing (see Supplementary Material). Women with evidence of active schistosome infection, 157 
defined by any positive urine examination (microscopy, Circulating Anodic Antigen (CAA) or 158 
PCR), or women with clinical evidence of FGS as determined by the midwife’s clinical 159 
examination (28), were treated free of charge with 40 mg/kg praziquantel, either at the clinic visit, 160 
or via community workers. 161 
 162 
Figure 1 – Genital Self-sampling Technique Utilized in the BILHIV Study 163 
 164 
Clinic-Based Sample Collection 165 
Enrolled women who were not currently menstruating were invited to attend Livingstone Central 166 
Hospital cervical cancer screening clinic within days of self-sampling, where one of two trained 167 
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midwives performed a cervicovaginal lavage (CVL). After speculum insertion, normal saline 168 
(10mL) was flushed continuously with a bulb syringe across the cervix and vaginal walls for one 169 
minute and collected from the posterior fornices. Images of the vagina and cervix were captured 170 
with a point-of-care colposcope (MobileODT, Tel Aviv, Israel). Participants with suspected 171 
reproductive tract infections were offered syndromic management, as per the Ministry of Health 172 
(29). Routine testing for reproductive tract infections was not performed in this study.  173 
 174 
Laboratory Analysis 175 
Urine aliquoting for quantification of CAA, PCR, and urinalysis were performed on the day of 176 
specimen arrival at the laboratory (see Supplementary Material). The remaining urine, up to 60mL 177 
per participant, was centrifuged in 15mL aliquots and examined by microscopy within 24 hours. 178 
The pellet from each 15mL urine aliquot (5 maximum) was evaluated for S. haematobium eggs. 179 
When a pellet contained at least one terminal-spined ovum, the participant was considered positive 180 
and the total number of counted eggs in the pellet was reported. Review of all positive and 10% of 181 
the negative specimens was conducted blinded by an expert for quality control. Dipsticks were 182 
used for analysis of hematuria and proteinuria (Multistix, Siemens, Germany). An up-converting 183 
reporter particle (UCP) lateral flow (LF) assay for the quantification of CAA in urine (0.4 mL) 184 
was performed at the Leiden University Medical Center (LUMC) (see Supplementary Material) 185 
(30). Urine CAA antigen levels are known to reflect adult worm burden and decline after 186 
successful treatment with praziquantel (31, 32).  187 
 188 
PCR for Schistosoma spp. 189 
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Pre-treatment and DNA isolation of CVL, genital swabs, and urine samples were performed (see 190 
Supplementary Material) in different sites at the LUMC, hence minor differences in the laboratory 191 
procedures. Briefly, genital swabs were suspended in PBS and vortexed, and thereafter handled as 192 
lavages, by pre-treating using a proteinase K heating step and isolating DNA using QIAamp spin 193 
columns (QIAGEN Benelux, Venlo, The Netherlands) (8, 12, 33). Two hundred µL of urine 194 
sample per participant were pretreated using Precellys Soil grinding SK38 (Bertin technology, 195 
Montigny-le-Bretonneux, France) and DNA was isolated using MagNA Pure 96 technology 196 
(Roche Diagnostics, Penzberg, Germany). Internal transcribed spacer 2-based real-time PCR was 197 
performed as previously described (33), with slight modifications (see Supplementary Material). 198 
DNA amplification and detection were performed with the CFX96 Real Time PCR Detection 199 
System (BioRad, California, USA). The output in threshold cycles (Ct) was analyzed using BioRad 200 
CFX software. Negative and positive control samples were included in each amplification run. 201 
Parasite DNA load is categorized by the following pre-specified Ct threshold for all specimens 202 
processed by PCR (urine, cervical swab, vaginal swab, and CVL): any Ct-value observed means 203 
positive and no Ct-value observed means negative (Supplementary Materials) (34). All specimens 204 
tested by PCR at LUMC were blinded for clinical and microscopy data. 205 
 206 
Ethical Considerations 207 
The study was approved by the University of Zambia Biomedical Research Ethics Committee 208 
(reference 011-08-17), the Zambia National Health Research Authority and the London School of 209 
Hygiene and Tropical Medicine Ethics Committee (reference 14506). Permission to conduct the 210 
study was given by Livingstone District health office and the superintendent of Livingstone 211 
Central Hospital. All the human subjects in this study were adults. 212 
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 213 
Statistical Methods 214 
We anticipated that the prevalence of S. haematobium infection would be 30% and that PCR 215 
performed on self-collected specimens would have sensitivity of 70% and specificity of 85%. 216 
Under these assumptions a sample size of 600 women would allow us to detect these target values 217 
with 95% confidence intervals of 63%-77% and 81%-88%, respectively. 218 
Data were entered on hand-held electronic data capture devices using Open Data Kit and analysed 219 
using STATA 15.1 (Stata Corporation, College Station, TX). Continuous variables were 220 
summarized by median and interquartile range (IQR), and categorical variables by frequency and 221 
percentage. Differences in participant characteristics between the two districts were evaluated 222 
using Fisher’s exact, chi-squared, and Wilcoxon-Mann-Whitney tests. The association between 223 
age group and positive test result was assessed using the test for trend. For the comparison of 224 
home-based self-collection methods with clinic based CVL, we calculated sensitivity and 225 
specificity. There weren’t indeterminate PCR results or missing data for genital self-collected 226 
swabs (the index test). “Definite” FGS was defined as any positive genital PCR (cervical swab, 227 
vaginal swab or CVL). The presence of either CAA or S. haematobium eggs in clinical specimens 228 
indicates the presence of infection with viable worms (30). Thus, in this study, “active” 229 
schistosome infection refers to participants with a positive urine PCR, CAA, or microscopy. To 230 
evaluate if sequential use of FGS diagnostics might be beneficial, an ad-hoc secondary analysis 231 
was performed in which calculation of the diagnostic performance was restricted to those with an 232 
active schistosome infection according to positive urine PCR, CAA, or microscopy. CVL was 233 
chosen as the a priori reference standard for the BILHIV study. In the absence of a universally 234 
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recognized reference standard for FGS, a composite FGS outcome was constructed, defined as a 235 
positive result on any genital PCR specimen (swab or CVL). 236 
Results: 237 
Overall, 1105 women in the study communities from the HPTN 071 (PopART) Population Cohort 238 
met the inclusion criteria. A total of 603 (54.5%) eligible women were enrolled with 527 (87.0%) 239 
completing clinic follow up (Figure 2). Women from both communities reported regular water 240 
contact in childhood (p=0.22) (Table 1). Overall, an active schistosome infection was diagnosed 241 
in 15.6% (94/601) (Table 2), of which 33 were urine microscopy positive and an additional 61 242 
cases were diagnosed by urine CAA. Urine PCR confirmed the presence of schistosome infection 243 
in 26 participants and did not detect any additional cases. Overall, 15.6% (94/601) schistosome 244 
infection (Table 2). The prevalence of S. haematobium infection was 5.5% (33/603) based on urine 245 
microscopy, 15.1% (91/601) by urine CAA, and 4.3% (26/601) by urine PCR (Table 2). 246 
 247 
Figure 2 – BILHIV Study Flow Diagram 248 
 249 
Table 1 – Baseline characteristics of 603 Zambian women living in S. haematobium endemic areas 250 
near the Zambezi river by district. 251 
 252 
Characteristics  Overall 
(n=603) 
Community A 
(n=319) 
Community B 
(n=284) 
p-value* 
Age in years – Median (IQR)  24 (22-28) 26 (23-29) 24 (21-27) <0.001 
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Marital Status Single 258 (42.8%) 110 (34.5%) 148 (52.1%) <0.001 
 Married or Cohabitating 320 (53.1%) 193 (60.5%) 127 (44.7%)  
 Divorced or Separated 23 (3.8%) 15 (4.7%) 8 (2.8%)  
 Widowed 2 (0.3%) 1 (0.3%) 1 (0.4%)  
 
Education (highest level) Any Primary School 167 (27.7%) 117 (36.7%) 50 (17.6%) <0.001 
 Any Secondary School 364 (60.4%) 173 (54.2%) 191 (67.3%)  
 Training in a Trade 59 (9.8%) 20 (6.3%) 39 (13.7%)  
 Degree or Higher 3 (0.5%) 3 (0.9%) 0 (0.0%)  
 None 10 (1.7%) 6 (1.9%) 4 (1.4%)  
 
Employment Status Working 408 (67.7%) 200 (62.7%) 208 (73.2%) 0.006 
 Not Working 195 (32.3%) 119 (37.3%) 76 (26.8%)  
 
Current Water Contact None 512 (84.9%) 263 (82.5%) 249 (87.7%) 0.02 
 At Least Weekly 18 (3.0%) 11 (3.5%) 7 (2.5%)  
 Every 1-2 Months 30 (5.0%) 24 (7.5%) 6 (2.1%)  
 Every 6-12 Months 43 (7.1%) 21 (6.6%) 22 (7.8%)  
 
Childhood Water Contact None 186 (30.9%) 96 (30.1%) 90 (31.7%) 0.22 
 At Least Weekly 381 (63.2%) 208 (65.2%) 173 (60.9%)  
 Every 1-2 Months 24 (4.0%) 12 (3.8%) 12 (4.2%)  
 Every 6-12 Months 12 (2.0%) 3 (0.9%) 9 (3.2%)  
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Self-reported History of 
Schistosomiasis 
No 572 (94.8%) 294 (92.2%) 278 (97.9%) 0.006 
Yes 25 (4.2%) 20 (6.3%) 5 (1.8%)  
Maybe 6 (1.0%) 5 (1.6%) 1 (0.4%) 
 
 
Self- reported Treatment 
with Praziquantel 
No 523 (86.7%) 270 (84.6%) 253 (89.1%) 0.11 
 Yes 61 (10.1%) 40 (12.5%) 21 (7.4%)  
 Maybe 19 (3.2%) 9 (2.8%) 10 (3.5%)  
* comparison of Community-A vs Community-B 253 
 254 
Table 2 – Diagnostic test results and FGS prevalence in 603 Zambian women living in S. 255 
haematobium endemic areas near the Zambezi river 256 
 257 
Characteristics Overall 
(n=603) 
% (n) 
Community-A 
(n=319)  
% (n) 
Community-B 
(n=284) 
% (n) 
p-value 
Hematuria 28.7 (173) 31.0 (99) 26.1 (74) 0.2 
Urine Microscopy 5.5 (33/603) 8.2 (26/319) 2.5 (7/284) 0.002 
Median egg count per 15mL‡ 18 17.5 18  
IQR 5 – 35 5 - 35 8 – 90  
Urine CAA* 15.1 (91/601) 20.5 (65/317) 9.2 (26/284) <0.001 
Median pg/mL‡ 9.10 11.46 5.93  
IQR 2.2 – 58.6 2.3 – 42.1 2.2 – 112.0  
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Urine PCR* 4.3 (26/601) 6.3 (20/317) 2.1 (6/284) 0.012 
Median Ct‡ 29.6 30.2 29.3  
IQR 27.8 – 33.5 26.4 – 34.9 29.0 – 32.7  
Active schistosome Infection*  
[any urine test positive] 
15.6 (94/601) 21.1 (67/317) 9.5 (27/284) <0.001 
PCR – CVL†  2.7 (14/527) 3.8 (11/290) 1.3 (3/237) 0.06** 
Median Ct‡ 34.6 35.3 33.2  
IQR 33.0 – 37.0 33.0 – 37.0 21.0 – 38.0  
PCR – Cervical Swab 3.3 (20/603) 4.4 (14/319) 2.1 (6/284) 0.12 
Median Ct‡ 35.3 35.8 33.3  
IQR 29.6 – 37.1 29.4 – 37.2 29.7 – 36.3  
PCR – Vaginal Swab 2.5 (15/603) 2.5 (8/319) 2.5 (7/284) 0.97 
Median Ct‡ 34.3 35.4 32.2  
IQR 23.6 – 37.1 30.6 – 37.2 23.2 – 35.2  
Any PCR Positive Sample†† 5.7 (30/529) 7.6 (22/291) 3.4 (8/238) 0.02 
 
PCR positive – Vaginal or 
Cervical Swab  
4.0 (24/603) 5.3 (17/319) 2.5 (7/284) 0.07 
 258 
*2 urine vials arrived at LUMC empty (n=601) 259 
** Calculated by Fisher’s exact (otherwise by chi-squared)  260 
† 527 women presented for CVL – 290 Community-A and 237 Community-B 261 
‡ Median egg count, CAA concentrations and PCR Ct-value restricted to positive tests 262 
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††One participant from each of Site-1 and Site-2 had positive self-collected PCR specimens but did 263 
not present to clinic (n=529) 264 
Abbreviations: CAA - Circulating Anodic Antigen, CVL – Cervicovaginal Lavage, PCR – 265 
Polymerase Chain Reaction for the detection of Schistosoma DNA 266 
 267 
There were 30 women (5.0%) with definite FGS, defined as any positive genital PCR (cervical 268 
swab, vaginal swab or CVL), 22/291 (7.6%) in Community-A and 8/238 (3.4%) in Community-B 269 
(p=0.04) and 95% (573/603) did not have definite FGS. The proportion of participants testing 270 
positive decreased with increasing age for all tests except urine CAA and CVL PCR (urine 271 
microscopy p-trend=0.004, urine PCR p-trend=0.003, any PCR-positive genital specimen p-272 
trend<0.001, cervical swab PCR p-trend<0.001, vaginal swab PCR p-trend<0.001) (Figure 3 & S1 273 
Table). In the 30 women with FGS, the prevalence of active schistosome infection was 70.0% 274 
(21/30). Of the 94 women with an active schistosome infection, 22.3% (21/94) had FGS and of 275 
the 507 women without active schistosome infection 1.8% (9/507) had FGS (p<0.001), these 276 
numbers include women who did not attend clinic follow-up. Figure 4 illustrates FGS diagnosis 277 
based on PCR positivity for each of the three genital sampling methods. No adverse events were 278 
reported in either group related to use of the index or reference test. 279 
 280 
Figure 3 Distribution of positive diagnostic test results by age group 281 
A. Distribution of positive urine CAA, urine microscopy, and urine PCR results by age group* 282 
 283 
B. Distribution of positive genital PCR results by age group* 284 
 285 
C. Distribution of any positive genital PCR result by age group* 286 
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 287 
*Please see Supplementary Table 1 for further details of the numbers of women tested per time point 288 
 289 
Figure 4 Venn Diagram of 28* Positive PCR-based Self-Collected Specimens (paired with CVL) 290 
for Schistosoma by Collection Type 291 
 292 
*2 participants with positive genital self-collected specimens did not follow up in clinic for 293 
Cervicovaginal Lavage 294 
 295 
The sensitivity of a positive result from any positive self-collected specimen (cervical or vaginal 296 
swab) against CVL was 57.1% (28.9 – 82.3) with specificity of 97.3% (95.5 – 98.5%) (Table 3). 297 
Compared with CVL, the sensitivity of self-collected cervical swabs (42.9% [17.7 – 71.1%]) was 298 
somewhat higher than for vaginal swabs (35.7% [12.8 – 64.9]), albeit with wide confidence 299 
intervals. The specificity of PCR in self-collected specimens versus CVL was high regardless of 300 
sampling technique (cervical 97.7% [95.9-98.8%], vaginal 98.2% [96.7-99.2%]) (Table 3). Self-301 
collected genital swabs were also evaluated as the reference standard (Table 3). Of these 302 
comparisons, the highest sensitivity (80% [61.4 – 92.3] was achieved using combined swab results 303 
compared with the composite FGS diagnosis (Table 3). 304 
 305 
Table 3 – Sensitivity and specificity of genital specimens for the detection of Schistosoma DNA 306 
by PCR 307 
 308 
Reference Standard Index test Sensitivity (%) Specificity (%) 
Sturt et al.                                                                                  Genital self-sampling for FGS diagnosis 
 
 
 18 
Cervicovaginal lavage PCR 
Vaginal swab PCR 35.7 [5/14] 
(12.8 – 64.9) 
98.2 [504/513]  
(96.7 – 99.2) 
Cervical swab PCR 42.9 [6/14] 
(17.7 – 71.1) 
97.7 [501/513] 
(95.9 – 98.8) 
Vaginal or Cervical Swab PCR 57.1 [8/14] 
(28.9 – 82.3) 
97.3 [499/513] 
(95.5 – 98.5) 
Cervical swab PCR 
Cervicovaginal Lavage PCR 33.3 [6/18] 
(13.3 – 59.0) 
98.4 [501/509] 
(96.9 – 99.3) 
Vaginal Swab PCR 55.0 [11/20] 
(31.5 – 76.9) 
99.3 [579/583] 
(98.3 – 99.8) 
Vaginal Swab PCR 
Cervicovaginal Lavage PCR 35.7 [5/14] 
(12.8 – 64.9) 
98.2 [504/513]  
(96.7 – 99.2) 
Cervical Swab PCR 73.3 [11/15] 
(44.9 – 92.2) 
98.5 [579/588] 
(97.1 – 99.3) 
Vaginal or Cervical Swab PCR 
Cervicovaginal Lavage PCR 36.4 [8/22] 
(17.2 – 59.3) 
98.8 [499/505] 
(97.4 – 99.6) 
Composite FGS Diagnosis* 
Vaginal swab PCR 50.0 [15/30] 
(31.3 – 68.7) 
100.0 [499/499] 
(99.3 – 100.0) 
Cervical swab PCR 66.7 [20/30] 
(47.2 – 82.7) 
100.0 [499/499] 
(99.3 – 100.0) 
Vaginal or Cervical Swab PCR 80.0 [24/30] 
(61.4 – 92.3) 
100.0 [499/499] 
(99.3 – 100.0) 
Cervicovaginal Lavage PCR 50.0 [14/28] 100.0 [499/499] 
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(30.6 – 69.4) (99.3 – 100.0) 
Abbreviations: CAA – Circulating Anodic Antigen, CS – Cervical Swab, CVL – Cervicovaginal 309 
Lavage, PCR – Polymerase Chain Reaction for the detection of Schistosoma DNA, VS – Vaginal 310 
Swab 311 
 312 
*Composite FGS Diagnosis – any positive PCR result on a genital specimen (CVL, vaginal swab or 313 
cervical swab) 314 
 315 
In a secondary analysis of those participants diagnosed with an active schistosome infection, the 316 
sensitivity of PCR from any positive self-collected swab specimen (cervical or vaginal) against 317 
CVL was marginally higher than in the primary analysis, albeit with wide confidence intervals 318 
(Table 4). The gain in sensitivity when evaluating those participants diagnosed with an active 319 
schistosome infection was accompanied by a decline in specificity (Table 4).  320 
 321 
Table 4 – Sub-analysis of sensitivity and specificity of self-collected genital swabs compared 322 
with cervicovaginal lavage for the detection of Schistosoma DNA in participants with positive 323 
urine specimens: CAA(n=78), microscopy (n=32), PCR (n=26) 324 
 325 
Reference test Index test Sensitivity (%) Specificity (%) 
Urine CAA 
 
Cervicovaginal lavage PCR 
 
Vaginal swab PCR 50.0 [4/8] 
(15.7 – 84.3) 
90.0 [63/70] 
(80.5 – 95.9) 
Cervical swab PCR 62.5 [5/8] 87.1 [61/70]  
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 (24.5 – 91.5) (77.0 – 93.9) 
Vaginal or cervical swab PCR 87.5 [7/8] 
(47.3 – 99.7) 
85.7 [60/70] 
(75.3 – 92.9) 
Urine Microscopy 
Cervicovaginal lavage PCR 
Vaginal swab PCR 55.6 [5/9] 
(21.2 – 86.3) 
73.9 [17/23] 
(51.6 – 89.3) 
Cervical swab PCR 66.7 [6/9] 
(29.9 – 92.5) 
56.5 [13/23] 
(34.5 – 76.8) 
Vaginal or cervical swab PCR 88.9 [8/9] 
(51.8 – 99.7) 
56.5 [13/23] 
(34.5 – 76.8) 
Urine PCR 
Cervicovaginal lavage PCR 
Vaginal swab PCR 55.6 [5/9] 
(21.2 – 86.3) 
70.6 [12/17] 
(44.0 – 89.7) 
Cervical swab PCR 66.7 [6/9] 
(29.9 – 92.5) 
47.1 [8/17] 
(23.0 – 72.2) 
Vaginal or cervical swab PCR 88.9 [8/9] 
(51.8 – 99.7) 
47.1 ([8/17] 
23.0 – 72.2) 
Active Schistosome Infection (Urine positive for PCR, CAA, or Microscopy) 
Cervicovaginal lavage PCR 
Vaginal swab PCR 55.6 [5/9] 
(21.2 – 86.3) 
90.3 [65/72] 
(81.0 – 96.0) 
Cervical swab PCR 66.7 [6/9] 
(29.9 – 92.5) 
86.1 [62/72] 
(75.9 – 93.1) 
Vaginal or cervical swab PCR 88.9 [8/9] 84.7 [61/72] 
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(51.8 – 99.7) (74.3 – 92.1) 
 326 
Discussion: 327 
The BILHIV study is the first to examine the performance of self-collected genital swabs (vaginal 328 
and cervical) for the diagnosis of FGS. Self-collected swabs were compared with provider-329 
collected CVL, an accepted, non-invasive standard for FGS diagnosis in research settings (12, 14). 330 
The addition of self-collected swabs to CVL increased the number of FGS diagnoses. The 331 
sensitivity of any self-collected genital specimen compared with CVL improved when only those 332 
diagnosed with an active infection (i.e. positive urine CAA, urine PCR, or urine microscopy) were 333 
considered. Using a composite definition of FGS (any PCR positive genital specimen) as the 334 
reference standard also improved the sensitivity of self-collected genital specimens. In the absence 335 
of a reference standard for FGS (21), the specificity of genital swabs is limited by comparison with 336 
CVL alone. CVL for FGS diagnosis has imperfect sensitivity and may not identify all true 337 
positives. In this analysis, the sensitivity of CVL as the index test compared to self-sampling as 338 
the reference was similar to that of self-sampling as the index test with CVL as reference standard.  339 
 340 
A sub-analysis of the BILHIV data also suggests that sensitivity of PCR-based testing of genital 341 
self-samples is high in the subgroup of participants with active infection. The cost of genital swabs 342 
(0.50$/vaginal swab and 0.30$/cervical swab) and molecular testing (6.68$/test) may be affordable 343 
in some research settings, but more field-appropriate and scalable NAAT methods should be 344 
investigated. Given the cost of FGS diagnostics, an algorithm which advocates FGS screening in 345 
resource-limited settings among women with positive CAA or urine microscopy could assist in 346 
conserving resources, labour, reagents, and other costs. Applying this algorithm to the BILHIV 347 
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study identifies 70.0% of FGS cases identified in a relatively low-prevalence area. However, an 348 
important limitation of restricting genital self-sampling to a sub-group with active infection is a 349 
decreased ability to detect FGS cases in the population, as FGS would not be identified in women 350 
without active infection. This decrement in the overall sensitivity of screening must be balanced 351 
against the availability of resources. Other practical limitations to this strategy include low 352 
prevalence populations, the imperfect sensitivity of Schistosoma PCR in genital self-sampling, and 353 
the current availability of PCR and CAA as research tools that do not yet allow individual rapid 354 
diagnosis at the point-of-care (35). To maximally leverage resources, FGS self-sampling would be 355 
integrated into other reproductive health platforms, ideally those that also utilize self-sampling in 356 
the diagnosis of reproductive tract infections, such as HPV (22, 25). 357 
 358 
Scalable, affordable, and field-acceptable diagnostics are necessary to improve our understanding 359 
of the current population prevalence of FGS and to limit the negative health impact of HIV-1, 360 
infertility, and gynaecologic symptoms. After repeated fresh-water exposures, girls living in 361 
endemic areas may develop the genital changes associated with FGS prior to sexual debut or the 362 
onset of menstruation (36). A single dose treatment of praziquantel will decrease egg production.  363 
but will only kill a proportion of living schistosomes (3). Data on the effect of praziquantel 364 
treatment in FGS are limited, with small numbers and heterogeneous methods, but do suggest a 365 
proportion of FGS lesions remain despite praziquantel treatment (37-39). Thus, early identification 366 
of FGS and subsequent praziquantel treatment prior to the age of 21 is associated with beneficial 367 
outcomes, such as lower prevalence of contact bleeding, lower odds of sandy patches (40), and 368 
lower rates of sub-fertility (41). Prevention efforts cannot be underestimated, and young women 369 
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should be prioritized to obtain the maximum benefit from the roll-out of FGS diagnosis and 370 
treatment. 371 
 372 
To date, no previous studies of FGS diagnostics have used CVL as a reference standard and cross-373 
study comparisons are limited due to heterogeneity of methods (8, 12, 14, 21). Previously 374 
published work has reported low sensitivity and high specificity of Schistosoma CVL PCR for 375 
FGS diagnosis in African populations (8, 14, 21). In adult Zimbabwean women (ages 15 – 49), 376 
CVL PCR sensitivity was 53% and specificity 79% compared with cervical visualization and 377 
histopathology (14). The study had some limitations relating to loss of specimens due to cold chain 378 
malfunctions, and extended specimen storage time (10 years), potentially affecting PCR outcomes. 379 
In an adolescent South African population (age range 15 – 23), CVL PCR was compared with 380 
urine microscopy, cervical visualization, and urogenital symptoms by latent class analysis with a 381 
sensitivity of 52.4% (33.2 – 73.6) and specificity of 42.4% (37.9 – 47.0) (21). Together, these 382 
studies further illustrate the limited performance of Schistosoma PCR in the absence of a reliable 383 
FGS reference standard (15).  384 
 385 
The performance of diagnostic tests for schistosome infection can vary by background parasite 386 
prevalence (42). Important information regarding disease stage, intensity and morbidity may be 387 
missed in the absence of appropriate diagnostics (31). No one test captures all characteristics of 388 
infection simultaneously and with perfect sensitivity. Conventional diagnostic tests (reagent strips 389 
and urine microscopy) are insensitive, especially in low-prevalence areas, where light intensity 390 
infections can be underestimated (42). The overall prevalence of schistosome infection in our study 391 
population was 5.5% by single urine microscopy, meeting the WHO classification of a low-risk 392 
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community (43). Egg detection in urine microscopy may increase slightly with serial urine 393 
collections (7, 44). The prevalence of FGS, as diagnosed by a positive PCR in any genital 394 
specimen, was 5.0% with site variations (2.8%-6.9%). Our study took place in two communities 395 
within Livingstone. Community-A is closer to a water source and women in Community-A had a 396 
higher overall prevalence of schistosome infection and FGS. The sensitivity of microscopy, urine 397 
PCR, and CAA diminish in areas of low parasite prevalence (42), or after treatment with 398 
praziquantel (44). Sensitivity of CAA can be increased by using a larger sample volume (45). Our 399 
results confirm previous findings that urine CAA has higher sensitivity than microscopy in low-400 
endemic settings (42) and further illustrates that schistosome infection is focal and prevalence can 401 
vary within neighbouring communities.  402 
 403 
When comparing the performance of sampling techniques for parasite DNA retrieval, cervical 404 
swabs detected 5 cases of FGS not detected by vaginal swabs and CVL. This was also true for 405 
vaginal swabs (2 FGS cases) and CVL (6 FGS cases) that were not detected in other sites examined 406 
by PCR-based methods (Figure 4). In the absence of self-collecting cervical cytology, it is not 407 
possible to confirm if the participants self-sampled from the cervix. However, the longer swab and 408 
collection techniques likely allowed a high cervicovaginal specimen that contributed to a greater 409 
number of PCR positive samples than vaginal swabs. Studies of FGS histopathology report the 410 
most common location for egg deposition is the cervix (6), which may explain the higher 411 
proportion of positive specimens in specimens detecting DNA from this site. Genital swabs are 412 
also field-appropriate, acceptable to participants, and scalable, while CVL requires vaginal 413 
speculum insertion and is performed by trained health workers.  414 
 415 
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The BILHIV study was conducted in a low prevalence area, therefore the presented estimates of 416 
sensitivity are subject to a high degree of imprecision due to the small numbers of total FGS cases. 417 
There was excellent retention with 87.4% (527/603) of participants presenting to the clinic for 418 
CVL, with very little missing data. The women self-collected vaginal and cervical specimens 419 
privately in their own homes. This raises the question of false negative genital swabs, which could 420 
be addressed by measuring B-globin PCR as a positive control to confirm the presence of human 421 
DNA (22). BILHIV data confirm previous findings that Schistosoma DNA can be detected in the 422 
genital tract in the absence of egg excretion (7, 8), and in participants with negative CAA. While 423 
these specimens may appear as false positives, the reported specificity of PCR for detecting 424 
Schistosoma DNA is  near 100% (14, 21). S. haematobium eggs can be detected in semen (46) and 425 
our study did not objectively evaluate for PSA or other markers of recent sexual contact. 426 
 427 
Overall, the relatively high concordance of DNA detection in genital self-collected specimens and 428 
CVL suggest that self-collection methods for the diagnosis of FGS are feasible in resource limited 429 
areas. Drawing on the experience of HPV, self-sampling has been shown to be scalable and 430 
effective in real-world settings (47). As the focus in schistosomiasis shifts from morbidity control 431 
to elimination, data on the performance of diagnostic tests for infection and morbidity in low-432 
prevalence settings becomes increasingly applicable (48). To achieve elimination of both infection 433 
and chronic disease such as FGS, low-prevalence areas require novel and innovative interventions 434 
and diagnostic strategies to provide site-appropriate, accurate prevalence estimates (48).  435 
 436 
Conclusion: 437 
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Genital self-sampling increased the overall number of PCR-based FGS diagnoses in a field setting, 438 
compared with cervicovaginal lavage. Schistosomiasis is focal and background parasite prevalence 439 
may impact test sensitivity. Home-based self-sampling may represent a scalable alternative 440 
method for FGS community-based diagnosis in endemic resource limited setting.  441 
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FIGURE TITLES & LEGENDS 621 
Figure 1 Title: Genital Self-sampling in the BILHIV Study 622 
Figure 1 Legend: A) Participants held a 6-inch vaginal swab at the 2 3/8-inch score mark, 623 
inserted the swab vaginally until their fingers touched the labia minora, and rotated the swab 624 
against the vaginal walls (minimum 15 repetitions). B) Participants held the 6 3/4-inch cervical 625 
swab at the non-flocked end, inserted the swab until their fingers touched the labia minora and/or 626 
encountered resistance, and rotated the swab against the place of resistance (minimum 15 627 
repetitions). 628 
 629 
Figure 2 Title: BILHIV Study Flow Diagram 630 
Figure 2 Legend: None 631 
 632 
Figure 3 Title: Distribution of positive diagnostic test results by age group 633 
A. Distribution of positive urine CAA, urine microscopy, and urine PCR results by age group* 634 
 635 
B. Distribution of positive genital PCR results by age group* 636 
 637 
C. Distribution of any positive genital PCR result by age group* 638 
 639 
Figure 3 Legend: 640 
*Please see Supplementary Table 1 for further details of the numbers of women tested per time point 641 
 642 
Figure 4 Title: Venn Diagram of 28* Positive PCR-based Self-Collected Specimens (paired with 643 
CVL) for Schistosoma by Collection Type 644 
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 645 
Figure 4 Legend: 646 
*2 participants with positive genital self-collected specimens did not follow up in clinic for 647 
cervicovaginal lavage 648 
 649 
